RU2010139315A - Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола - Google Patents

Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола Download PDF

Info

Publication number
RU2010139315A
RU2010139315A RU2010139315/04A RU2010139315A RU2010139315A RU 2010139315 A RU2010139315 A RU 2010139315A RU 2010139315/04 A RU2010139315/04 A RU 2010139315/04A RU 2010139315 A RU2010139315 A RU 2010139315A RU 2010139315 A RU2010139315 A RU 2010139315A
Authority
RU
Russia
Prior art keywords
further characterized
crystalline modification
peaks
exhibits
modification according
Prior art date
Application number
RU2010139315/04A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид Александр ЛИРМОНТ (PT)
Дэвид Александр ЛИРМОНТ
Кейт ЛОРИМЕР (US)
Кейт ЛОРИМЕР
Кевин Уэйн МЕЙЕР (US)
Кевин Уэйн МЕЙЕР
Тибор ЭСЕНЬИ (HU)
Тибор ЭСЕНЬИ
Альмошне КОВАЧ (HU)
Альмошне КОВАЧ
Original Assignee
Биал - Портела Энд Ка., С.А. (Pt)
Биал - Портела Энд Ка., С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биал - Портела Энд Ка., С.А. (Pt), Биал - Портела Энд Ка., С.А. filed Critical Биал - Портела Энд Ка., С.А. (Pt)
Publication of RU2010139315A publication Critical patent/RU2010139315A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2010139315/04A 2008-03-17 2009-03-16 Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола RU2010139315A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6972108P 2008-03-17 2008-03-17
US61/069,721 2008-03-17

Publications (1)

Publication Number Publication Date
RU2010139315A true RU2010139315A (ru) 2012-04-27

Family

ID=40585552

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010139315/04A RU2010139315A (ru) 2008-03-17 2009-03-16 Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола

Country Status (16)

Country Link
US (2) US8975410B2 (enExample)
EP (1) EP2276758B1 (enExample)
JP (2) JP2011514380A (enExample)
KR (1) KR20110002462A (enExample)
CN (1) CN102015696A (enExample)
AR (1) AR070907A1 (enExample)
AU (1) AU2009226221A1 (enExample)
BR (1) BRPI0908731A2 (enExample)
CA (1) CA2718772C (enExample)
CL (1) CL2009000628A1 (enExample)
ES (1) ES2565080T3 (enExample)
IL (1) IL207854A0 (enExample)
MX (1) MX2010009610A (enExample)
RU (1) RU2010139315A (enExample)
TW (1) TW200942531A (enExample)
WO (1) WO2009116882A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1907382T1 (sl) 2005-07-26 2015-10-30 Bial-Portela & Ca S.A., Nitrokateholni derivati kot inhibitorji COMT
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
ES2597705T3 (es) 2007-01-31 2017-01-20 Bial - Portela & Ca., S.A. Derivados de nitrocatecol como inhibidores de COMT administrados con un régimen de dosificación específico
EP2276758B1 (en) 2008-03-17 2016-01-06 Bial-Portela & CA, S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol
PT2307020T (pt) * 2008-07-29 2019-05-28 Bial Portela & Ca Sa Regime de administração de nitrocatecólicos
KR102329271B1 (ko) * 2009-04-01 2021-11-22 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
AU2010231962B2 (en) * 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
US9848134B2 (en) 2010-04-23 2017-12-19 Flir Systems, Inc. Infrared imager with integrated metal layers
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
PL2791134T3 (pl) * 2011-12-13 2020-03-31 BIAL - PORTELA & Cª S.A. Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
EP3298008B1 (en) * 2015-05-20 2019-11-20 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
RU2659987C2 (ru) * 2016-12-07 2018-07-04 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Планарный твердофазный оптический сенсор для определения белковых соединений методом спектроскопии гигантского комбинационного рассеяния и его применение для детектирования белковых соединений
JP2023517690A (ja) * 2020-03-13 2023-04-26 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ 微粉化オピカポン
GB202011709D0 (en) 2020-07-28 2020-09-09 Bial Portela & Ca Sa Solid dispersion of opicapone
GB202016425D0 (en) 2020-10-16 2020-12-02 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
WO2022131944A1 (en) 2020-12-17 2022-06-23 Bial-Portela & Ca., S.A. Treatment regimens for early idiopathic parkinson's disease
GB202219669D0 (en) 2022-12-23 2023-02-08 Bial Portela & Ca Sa Processes and intermediates for synthesising opicapone
AU2023449890A1 (en) 2023-05-25 2025-11-27 Bial-Portela & Ca., S.A. Treatment regimens for early idiopathic parkinson's disease

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1532178A (en) 1921-07-25 1925-04-07 Louis A Godbold Lubricator
FR1260080A (fr) 1960-03-22 1961-05-05 Materiel De Forage Soc De Fab Trépan à molettes étanche
US3647809A (en) 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4264573A (en) 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4386668A (en) 1980-09-19 1983-06-07 Hughes Tool Company Sealed lubricated and air cooled rock bit bearing
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
DE3840954A1 (de) 1988-12-05 1990-06-07 Shell Int Research Herstellung von 2-chlornicotinsaeureestern
US5206372A (en) 1990-06-05 1993-04-27 Shell Research Limited Preparation of 2-chloropyridine derivatives
DE69013689T2 (de) 1990-11-29 1995-03-02 Wei Ming Pharmaceutical Mfg Co Hilfsträger für direkte Verpressung.
AU3171493A (en) 1991-12-31 1993-07-28 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
FR2730322B1 (fr) 1995-02-02 1997-04-30 Imago Monture de lunettes metallique
DE19628617A1 (de) 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
US6206110B1 (en) 1996-09-09 2001-03-27 Smith International, Inc. Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit
CA2337755C (en) 1998-09-18 2008-07-29 Vertex Pharmaceuticals Incorporated Inhibitors of p38
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
IL131037A (en) 1999-07-22 2004-06-20 Israel Atomic Energy Comm Method for making threedimensional photonic band-gap crystals
ATE307129T1 (de) 1999-08-19 2005-11-15 Nps Pharma Inc Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
FI20000635A0 (fi) 2000-03-17 2000-03-17 Orion Yhtymae Oyj COMT-inhibiittoreiden käyttö analgeettina
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
GB2363792A (en) 2000-06-21 2002-01-09 Portela & Ca Sa Nitrocatechols
JP3965361B2 (ja) 2000-08-24 2007-08-29 佐川急便株式会社 物流又は運送に関わるサービス料金のカード決済方法及びそのシステム
CN1166626C (zh) 2000-08-30 2004-09-15 李凌松 三或四取代苯基化合物、其制备方法及应用
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
CA2436739A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
PL369598A1 (en) 2001-02-21 2005-05-02 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AU2002310187A1 (en) 2001-05-30 2002-12-09 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
CN1638776A (zh) 2001-06-08 2005-07-13 西托维亚公司 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
MXPA04000775A (es) 2001-07-26 2004-04-20 Merck Patent Ges Mit Baschrank Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.
JP4379853B2 (ja) 2001-10-05 2009-12-09 惠民製藥股▲分▼有限公司 直接錠剤化用調合物および補助剤の調合方法
EP1581213A4 (en) 2002-12-18 2008-11-19 Cytovia Inc 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLE AND ANALOGUE TO ACTIVATE CASPASE AND INTRODUCTION OF APOPTOSIS AND THEIR USE
WO2005006945A2 (en) 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
AR045731A1 (es) 2003-08-06 2005-11-09 Vertex Pharma Compuestos de aminotriazol utiles como inhibidores de quinasas de proteinas
US7300406B2 (en) 2003-09-30 2007-11-27 Carter Vandette B Medical examination apparatus
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1751133B1 (en) 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US20060173074A1 (en) 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
WO2006061697A1 (en) 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
WO2006071184A1 (en) 2004-12-28 2006-07-06 Astrazeneca Ab Aryl sulphonamide modulators
US20080051441A1 (en) 2004-12-28 2008-02-28 Astrazeneca Ab Aryl Sulphonamide Modulators
JP2008539195A (ja) 2005-04-26 2008-11-13 ノイロサーチ アクティーゼルスカブ 新規のオキサジアゾール誘導体及びそれらの医学的使用
US20060257473A1 (en) 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US7553964B2 (en) 2005-06-03 2009-06-30 Abbott Laboratories Cyclobutyl amine derivatives
US20090000437A1 (en) 2005-07-14 2009-01-01 Provo Craft And Novelty, Inc. Methods for Cutting
SI1907382T1 (sl) 2005-07-26 2015-10-30 Bial-Portela & Ca S.A., Nitrokateholni derivati kot inhibitorji COMT
FR2889525A1 (fr) 2005-08-04 2007-02-09 Palumed Sa Nouveaux derives de polyquinoleines et leur utilisation therapeutique.
US20070048384A1 (en) 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
EP1954137A4 (en) 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE
US8022075B2 (en) 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
JP2008162955A (ja) 2006-12-28 2008-07-17 Chugai Pharmaceut Co Ltd バリン含有高密度顆粒剤
ES2597705T3 (es) 2007-01-31 2017-01-20 Bial - Portela & Ca., S.A. Derivados de nitrocatecol como inhibidores de COMT administrados con un régimen de dosificación específico
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
JP5718053B2 (ja) 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド 治療用イソオキサゾール化合物
EP2259777A2 (en) 2008-02-28 2010-12-15 BIAL - Portela & Ca., S.A. Pharmaceutical composition for poorly soluble drugs
EP2276758B1 (en) 2008-03-17 2016-01-06 Bial-Portela & CA, S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol
PT2307020T (pt) 2008-07-29 2019-05-28 Bial Portela & Ca Sa Regime de administração de nitrocatecólicos
US8827197B2 (en) 2008-11-04 2014-09-09 Microgreen Polymers Inc Apparatus and method for interleaving polymeric roll for gas impregnation and solid-state foam processing
AU2010231962B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
KR102329271B1 (ko) 2009-04-01 2021-11-22 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
WO2011107653A2 (en) 2010-03-04 2011-09-09 Orion Corporation Method for treating parkinson's disease
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
PL2791134T3 (pl) 2011-12-13 2020-03-31 BIAL - PORTELA & Cª S.A. Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy

Also Published As

Publication number Publication date
KR20110002462A (ko) 2011-01-07
JP2011514380A (ja) 2011-05-06
MX2010009610A (es) 2010-09-30
EP2276758B1 (en) 2016-01-06
IL207854A0 (en) 2010-12-30
EP2276758A1 (en) 2011-01-26
US9845316B2 (en) 2017-12-19
CA2718772A1 (en) 2009-09-24
CA2718772C (en) 2017-05-02
AU2009226221A1 (en) 2009-09-24
TW200942531A (en) 2009-10-16
AR070907A1 (es) 2010-05-12
BRPI0908731A2 (pt) 2017-05-16
JP2015044837A (ja) 2015-03-12
CN102015696A (zh) 2011-04-13
ES2565080T3 (es) 2016-03-31
WO2009116882A1 (en) 2009-09-24
US20150166519A1 (en) 2015-06-18
US8975410B2 (en) 2015-03-10
US20110112301A1 (en) 2011-05-12
CL2009000628A1 (es) 2010-04-09

Similar Documents

Publication Publication Date Title
RU2010139315A (ru) Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола
JP2011514380A5 (enExample)
KR101730937B1 (ko) 베타-세크레타아제(ｂａｃｅ) 저해제로 유용한 5,6-디하이드로-2ｈ-[1,4]옥사진-3-일-아민 유도체
CN103958469B (zh) 一种新的普利多匹定盐酸盐多晶型形态
JP2020164541A (ja) 多環式化合物及びその使用方法
RU2008143362A (ru) Сокристаллическая форма производного с-гликозида c l-пролином
KR100839265B1 (ko) 치환된 티오아세트아미드
NZ602754A (en) Substituted 1,3-benzothiazepines useful in treating metabolic disorders
WO2013131018A1 (en) Biaryl inhibitors of the sodium channel
JP2010514806A5 (enExample)
TWI356825B (en) (1s,5s)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicy
Maghari et al. A new and efficient synthesis of 1, 3, 4-oxadiazole derivatives using TBTU
KR20130094179A (ko) 대사형 글루탐산 수용체 양성 알로스테릭 조정자의 다형체
JP2008524262A5 (enExample)
JP2018515569A (ja) キナーゼを調節するための化合物の固体形態
AU2012257360B2 (en) Polymorph of Rifaximin and process for the preparation thereof
CA2727378A1 (en) New co-crystal compound of rivaroxaban and malonic acid
CN109734690B (zh) 新abexinostate盐、相关的晶体形式、其制备方法以及含有其的药物组合物
WO2015083071A1 (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
HUE035731T2 (hu) (S)-(2-(6-klór-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2- (2H-l,2,3-triazol-2-il)fenil)metanon kristályos formája és alkalmazása orexin receptor antagonistaként
CN107810183A (zh) (s)‑[3,4‑二氟‑2‑(2‑氟‑4‑碘苯基氨基)苯基][3‑羟基‑3‑(哌啶‑2‑基)氮杂环丁烷‑1‑基]‑甲酮的结晶反丁烯二酸盐
Snyder et al. Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the stereogenic center found in oxazolidinone antibacterials
RU2731913C2 (ru) Пиперазиновое производное
JP2019518058A (ja) スピロ−オキシインドール化合物の固体状態形
RU2009103040A (ru) Полиморфы n-(2-ацетил-4,6-диметилфенил)-3-{[4-диметил-5-изоксазолил)амино]сульфонил}-2-тиофен-карбоксамида